Logo image of OBIO

ORCHESTRA BIOMED HOLDINGS IN (OBIO) Stock Fundamental Analysis

USA - Nasdaq - NASDAQ:OBIO - US68572M1062 - Common Stock

4.59 USD
+0.02 (+0.44%)
Last: 12/12/2025, 9:47:38 AM
Fundamental Rating

2

Overall OBIO gets a fundamental rating of 2 out of 10. We evaluated OBIO against 187 industry peers in the Health Care Equipment & Supplies industry. The financial health of OBIO is average, but there are quite some concerns on its profitability. OBIO has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year OBIO has reported negative net income.
In the past year OBIO has reported a negative cash flow from operations.
In the past 5 years OBIO always reported negative net income.
In the past 5 years OBIO always reported negative operating cash flow.
OBIO Yearly Net Income VS EBIT VS OCF VS FCFOBIO Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

OBIO's Return On Assets of -71.66% is on the low side compared to the rest of the industry. OBIO is outperformed by 74.33% of its industry peers.
OBIO's Return On Equity of -171.70% is on the low side compared to the rest of the industry. OBIO is outperformed by 70.05% of its industry peers.
Industry RankSector Rank
ROA -71.66%
ROE -171.7%
ROIC N/A
ROA(3y)-56.32%
ROA(5y)-79.02%
ROE(3y)-108.38%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
OBIO Yearly ROA, ROE, ROICOBIO Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 0 -500 -1K

1.3 Margins

With an excellent Gross Margin value of 93.01%, OBIO belongs to the best of the industry, outperforming 98.93% of the companies in the same industry.
OBIO's Gross Margin has declined in the last couple of years.
The Profit Margin and Operating Margin are not available for OBIO so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 93.01%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-9.78%
GM growth 5YN/A
OBIO Yearly Profit, Operating, Gross MarginsOBIO Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024 0 1K -1K 2K -2K

More info and screens

4

2. Health

2.1 Basic Checks

OBIO does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for OBIO has been increased compared to 1 year ago.
OBIO has a worse debt/assets ratio than last year.
OBIO Yearly Shares OutstandingOBIO Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 10M 20M 30M
OBIO Yearly Total Debt VS Total AssetsOBIO Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 20M 40M 60M 80M

2.2 Solvency

OBIO has an Altman-Z score of -3.85. This is a bad value and indicates that OBIO is not financially healthy and even has some risk of bankruptcy.
OBIO has a Altman-Z score of -3.85. This is in the lower half of the industry: OBIO underperforms 67.91% of its industry peers.
A Debt/Equity ratio of 0.32 indicates that OBIO is not too dependend on debt financing.
Looking at the Debt to Equity ratio, with a value of 0.32, OBIO is in line with its industry, outperforming 50.27% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 0.32
Debt/FCF N/A
Altman-Z -3.85
ROIC/WACCN/A
WACC8.64%
OBIO Yearly LT Debt VS Equity VS FCFOBIO Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M

2.3 Liquidity

A Current Ratio of 4.73 indicates that OBIO has no problem at all paying its short term obligations.
The Current ratio of OBIO (4.73) is better than 74.87% of its industry peers.
A Quick Ratio of 4.72 indicates that OBIO has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 4.72, OBIO belongs to the top of the industry, outperforming 81.28% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 4.73
Quick Ratio 4.72
OBIO Yearly Current Assets VS Current LiabilitesOBIO Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 20M 40M 60M 80M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for OBIO have decreased strongly by -12.42% in the last year.
The Revenue has been growing slightly by 6.46% in the past year.
EPS 1Y (TTM)-12.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2.44%
Revenue 1Y (TTM)6.46%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-12.77%

3.2 Future

Based on estimates for the next years, OBIO will show a quite strong growth in Earnings Per Share. The EPS will grow by 14.48% on average per year.
OBIO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 79.87% yearly.
EPS Next Y-7.65%
EPS Next 2Y1.9%
EPS Next 3Y8.95%
EPS Next 5Y14.48%
Revenue Next Year6.42%
Revenue Next 2Y4.47%
Revenue Next 3Y-6.73%
Revenue Next 5Y79.87%

3.3 Evolution

OBIO Yearly Revenue VS EstimatesOBIO Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 50M 100M 150M
OBIO Yearly EPS VS EstimatesOBIO Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -2 -4 -6 -8

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

OBIO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for OBIO. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
OBIO Price Earnings VS Forward Price EarningsOBIO Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
OBIO Per share dataOBIO EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 0.5 -0.5 -1 -1.5

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.9%
EPS Next 3Y8.95%

More info and screens

0

5. Dividend

5.1 Amount

OBIO does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ORCHESTRA BIOMED HOLDINGS IN

NASDAQ:OBIO (12/12/2025, 9:47:38 AM)

4.59

+0.02 (+0.44%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)11-10 2025-11-10/amc
Earnings (Next)N/A N/A
Inst Owners29.38%
Inst Owner Change27.39%
Ins Owners3.03%
Ins Owner Change5.83%
Market Cap259.15M
Revenue(TTM)2.82M
Net Income(TTM)-75.10M
Analysts81.54
Price Target13.6 (196.3%)
Short Float %2.45%
Short Ratio2.86
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)6.25%
Min EPS beat(2)2.68%
Max EPS beat(2)9.82%
EPS beat(4)4
Avg EPS beat(4)4.05%
Min EPS beat(4)0.13%
Max EPS beat(4)9.82%
EPS beat(8)7
Avg EPS beat(8)2.55%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)2
Avg Revenue beat(2)14.62%
Min Revenue beat(2)11.42%
Max Revenue beat(2)17.83%
Revenue beat(4)3
Avg Revenue beat(4)5.09%
Min Revenue beat(4)-70.51%
Max Revenue beat(4)61.63%
Revenue beat(8)4
Avg Revenue beat(8)-7.94%
Revenue beat(12)6
Avg Revenue beat(12)-2.62%
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.23%
PT rev (3m)-3.61%
EPS NQ rev (1m)5.45%
EPS NQ rev (3m)18.99%
EPS NY rev (1m)0.93%
EPS NY rev (3m)9.93%
Revenue NQ rev (1m)-0.46%
Revenue NQ rev (3m)13.38%
Revenue NY rev (1m)3.81%
Revenue NY rev (3m)13.86%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 91.96
P/FCF N/A
P/OCF N/A
P/B 5.92
P/tB 5.92
EV/EBITDA N/A
EPS(TTM)-1.81
EYN/A
EPS(NY)-1.6
Fwd EYN/A
FCF(TTM)-1.09
FCFYN/A
OCF(TTM)-1.07
OCFYN/A
SpS0.05
BVpS0.77
TBVpS0.77
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -71.66%
ROE -171.7%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 93.01%
FCFM N/A
ROA(3y)-56.32%
ROA(5y)-79.02%
ROE(3y)-108.38%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-9.78%
GM growth 5YN/A
F-Score4
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity 0.32
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 353.8%
Cap/Sales 41.31%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.73
Quick Ratio 4.72
Altman-Z -3.85
F-Score4
WACC8.64%
ROIC/WACCN/A
Cap/Depr(3y)194.88%
Cap/Depr(5y)224.07%
Cap/Sales(3y)17.77%
Cap/Sales(5y)19.48%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-12.42%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%2.44%
EPS Next Y-7.65%
EPS Next 2Y1.9%
EPS Next 3Y8.95%
EPS Next 5Y14.48%
Revenue 1Y (TTM)6.46%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-12.77%
Revenue Next Year6.42%
Revenue Next 2Y4.47%
Revenue Next 3Y-6.73%
Revenue Next 5Y79.87%
EBIT growth 1Y-25.18%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-13.47%
EBIT Next 3Y-4.54%
EBIT Next 5Y4.75%
FCF growth 1Y-39.47%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-37.23%
OCF growth 3YN/A
OCF growth 5YN/A

ORCHESTRA BIOMED HOLDINGS IN / OBIO FAQ

Can you provide the ChartMill fundamental rating for ORCHESTRA BIOMED HOLDINGS IN?

ChartMill assigns a fundamental rating of 2 / 10 to OBIO.


What is the valuation status of ORCHESTRA BIOMED HOLDINGS IN (OBIO) stock?

ChartMill assigns a valuation rating of 0 / 10 to ORCHESTRA BIOMED HOLDINGS IN (OBIO). This can be considered as Overvalued.


Can you provide the profitability details for ORCHESTRA BIOMED HOLDINGS IN?

ORCHESTRA BIOMED HOLDINGS IN (OBIO) has a profitability rating of 1 / 10.


What is the earnings growth outlook for ORCHESTRA BIOMED HOLDINGS IN?

The Earnings per Share (EPS) of ORCHESTRA BIOMED HOLDINGS IN (OBIO) is expected to decline by -7.65% in the next year.